GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us. Yuen MF et al. Hepatitis B virus (HBV) surface antigen (HBsAg) inhibition with ISIS 505358 in chronic hepatitis B (CHB) patients on stable nucleos(t)ide analogue (NA) regimen and in NA -naive CHB patients: phase 2a, randomized, double-blind, placebo-controlled study. Abstract No. AS067. The Digital International Liver Congress 2020. CONCORD, Mass.--( BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract entitled ‘Therapeutic vaccination with CLB-3000 in a mouse model of chronic Hepatitis B induces anti-HBs responses associated with functional cure’ was accepted for poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2022, taking place in London, UK June 22 - 26, 2022.

The end of study results will be presented today at the American Association for the Study of Liver Diseases’ Liver Meeting 2022 (AASLD) in Washington DC, and simultaneously published in the New England Journal of Medicine.

About GSK3228836

Chronic hepatitis B is a major global health problem caused by the hepatitis B virus. It is a long-lasting infection that occurs when the body’s immune system is unable to fight off the virus enabling it to persist in the blood and liver. Current treatment options, which include nucleoside/nucleotide analogues, can suppress but not clear the virus, so need to be taken for life.

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK’s Q3 Results for 2022 and any impacts of the COVID-19 pandemic. Four abstracts on linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor for patients with cholestatic pruritus associated with primary biliary cholangitis (PBC). These include a Decentralized Clinical Trial (DCT) design with the potential to improve patient recruitment and retention in the GLISTEN phase III trial; CONCORD, Mass.--( BUSINESS WIRE)-- ClearB Therapeutics, Inc., now a clinical-stage biotechnology company committed to developing therapies to drive functional cure in patients with chronic hepatitis B (CHB) infection, announced that the first patient has been dosed in the Phase 1b clinical study evaluating the therapeutic vaccine CLB-3000 ( ACTRN1263000841673). Satisfactory review of safety data for this patient supported opening enrollment for the remainder of the cohort.An abstract describing T-cell immunogenicity data on the chronic hepatitis B targeted immunotherapy (CHB-TI) obtained from the sequential arm of a phase I/II trial on the CHB-TI as monotherapy;

Phase II trial of bepirovirsen in sequential combination with GSK’s chronic hepatitis B targeted immunotherapy. In the NA-naïve group (n=12), average [SD] reduction reached -1.56 [1.38] log 10 IU/ml vs. placebo 0.00 [0.11], n=6, p=0.001. Three of these patients had reductions ≥3.0 log 10 IU/mL by Day 29. Bepirovirsen is an investigational antisense oligonucleotide (ASO) designed to specifically recognise the RNA that the hepatitis B virus uses to replicate itself in the infected liver cells (hepatocytes) and make the viral antigens (proteins) which facilitate chronicity of the disease by helping to avoid clearance by the immune system. The ASO recruits the liver’s own enzymes to eliminate the RNA by digesting it to an inactive form. The subsequent reduction in the levels of the RNA results in a decrease in both the virus and the production of viral antigen (HBsAg) by the hepatocytes, which can be measured by a drop in the HBV DNA and antigen levels in the circulating blood. Bepirovirsen has an additional property of stimulating immune responses via Toll-like receptor 8 (TLR8) which may help the immune system to achieve durable clearance of the virus from circulating blood. The results offer an early indication that bepirovirsen might be a potential treatment, either as monotherapy or in combination with NAs, that could result in functional cure. In addition, the trial identified a potential patient sub-group more likely to benefit from treatment with bepirovirsen, helping to guide future development. In addition, ClearB Therapeutics announced the acceptance of an abstract including new preclinical data for a humanized monoclonal antibody as serotherapy for the treatment of CHB for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2023, taking place in Boston, MA November 10 – 14, 2023.The b-clear anti-viral sanitiser is scientifically proven to be effective at eradicating Coronavirus.

External scientific engagement on the start of the phase IIb study of GSK4532990 in adults with nonalcoholic steatohepatitis (NASH). GSK today announced that GSK’836 (GSK3228836), an investigational antisense oligonucleotide, showed marked reductions in hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA compared with placebo after four weeks treatment in people with chronic hepatitis B on stable nucleoside or nucleotide analogue (NA) therapy and in patients who were NA-naïve. We are beyond thrilled to be able to advance our therapeutic vaccine candidate, CLB-3000, toward first in human trials in patients with CHB. We look forward to sharing emerging clinical data with the Hepatitis B community as it becomes available” said Aileen Rubio, PhD, CEO for the company. “CHB infection remains a substantial global health care problem in need of safe and effective therapies. We believe that boosting of patients’ own immune system with ClearB’s therapeutic vaccine, CLB-3000, could become an important component of evolving combination treatment regimens.” There are other types of data that are related to your behavior online. These other types of data can be deleted separately:There is a need for therapeutic approaches that enable not only suppression of viral replication, but resolution of chronic HBV infection. About GSK3228836 GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk Factors" in the company's Annual Report on Form 20-F for 2019 and as set out in GSK’s “Principal risks and uncertainties” section of the Q2 Results and any impacts of the COVID-19 pandemic.